\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Horizon EuropeThe Commission has adopted the amendment to the Horizon Europe ‘main’ work programme 2023-2024 and limited extension to 2025. It includes the Marie Skłodowska-Curie Actions, Research Infrastructures, all the Clusters under pillar II, Missions, European Innovation Ecosystems and Widening Participation & strengthening the European Research Area.
The amendment includes a substantional update for the Missions with a range of new topics/calls (using 2024 budget), following the outcomes of the EU Missions assessment.
The adopted texts with the updates to the work programme have been made available in pdf form on the Funding & Tenders Portal (under reference documents here). Information on the specific changes applicable to the different Horizon Europe subprogrammes, will be published on the respective subdomain pages on our website.
The limited extension to 2025 concerns, among others, new topics/calls using 2025 budget, only for recurrent actions without strong political focus and with a strong need for continuity (among others Marie Skłodowska-Curie Actions & Widening participation). However, the main Horizon Europe Work Programme 2025 is still under developments and is expected only to be officially published in the first months of 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
